<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03791190</url>
  </required_header>
  <id_info>
    <org_study_id>RCA for CRRT in liver failure</org_study_id>
    <nct_id>NCT03791190</nct_id>
  </id_info>
  <brief_title>RCA for CRRT in Liver Failure and High Risk Bleeding Patients</brief_title>
  <official_title>The Efficacy and Safety of Regional Citrate Anticoagulation Versus No-anticoagulation for CRRT in Patients With Liver Failure and High Risk Bleeding: a Randomized, Control, Open-labeled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this single center, randomized, control, open-labeled study is to evaluate the
      effect and safety of RCA versus no anticoagulation for CRRT in patients with liver failure
      and high risk bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver failure (LF) is a common co-morbidity in critical care patients who need continuous
      renal replacement therapy (CRRT). Patients with LF are usually associated with impaired
      coagulation, impaired metabolic ability of anticoagulants, and increased bleeding risk. KDIGO
      guideline recommended no-anticoagulation for CRRT in patients with liver failure and
      increased bleeding risk. However, the averaged CRRT circuit lifespan under no-coagulation was
      reported to be 7-8 hours in patients with liver failure. Commonly, a CRRT regimen needs more
      than 24 hours treatment, which means 3-4 filters replacement for one regimen in liver failure
      patients underwent no-anticoagulation CRRT. Several observational studies suggested that
      regional citrate anticoagulation (RCA) during CRRT was effective and safe in patients with
      liver failure. Therefore, the current opinions on the anticoagulation strategy for CRRT in
      patients with liver failure and high bleeding risk are controversial. Therefore, the purpose
      of this single center, randomized, control, open-labeled study is to evaluate the effect and
      safety of RCA versus no anticoagulation for CRRT in patients with liver failure and high risk
      bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Filter failure</measure>
    <time_frame>72 hours</time_frame>
    <description>Filter failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Total Ca2+/ion Ca2+ level</measure>
    <time_frame>2, 6, 12, 20, 28, 36, 44, 52, 60, and 72 hours.</time_frame>
    <description>Serum Total Ca2+/ ionized Ca2+ level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypocalcemia</measure>
    <time_frame>72 hours</time_frame>
    <description>Ionized Ca2+ &lt; 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acidosis</measure>
    <time_frame>72 hours</time_frame>
    <description>Blood pH &lt; 7.35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkalosis</measure>
    <time_frame>72 hours.</time_frame>
    <description>Blood pH &gt; 7.45</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>72 hours</time_frame>
    <description>Bleeding episode during the CRRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum citrate concentration</measure>
    <time_frame>2, 6, 12, 20, 28, 36, 44, 52, 60, and 72 hours.</time_frame>
    <description>Citrate concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total bilirubin level</measure>
    <time_frame>Every 24 hours up to 72 hours.</time_frame>
    <description>Total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AST level</measure>
    <time_frame>Every 24 hours up to 72 hours.</time_frame>
    <description>AST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ALT level</measure>
    <time_frame>Every 24 hours up to 72 hours.</time_frame>
    <description>ALT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>No-anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional citrate anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.
Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regional citrate anticoagulation</intervention_name>
    <description>Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.</description>
    <arm_group_label>Regional citrate anticoagulation</arm_group_label>
    <other_name>RCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No-anticoagulation</intervention_name>
    <description>Patients accepted CRRT without anticoagulant.</description>
    <arm_group_label>No-anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver failure (acute liver failure and chronic liver failure)

          -  High bleeding risk

          -  Scheduled CRRT treatment

          -  Informed consent

        Exclusion Criteria:

          -  Use of other anticoagulants

          -  Uncorrectable hypoxemia (PaO2 &lt; 60 mmHg) or systemic hypoperfusion shock

          -  Pregnancy or lactation

          -  Fistula, CRRT treatment time &lt; 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiren Sun, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital, the Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming Bai, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital, the Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiren Sun, Doctor</last_name>
    <phone>+8602984775193</phone>
    <email>sunshiren@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Bai, Doctor</last_name>
    <phone>sunshiren@medmail.com.cn</phone>
    <email>mingbai1983@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of Nephrology</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiren Sun, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>sunshiren@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ming Bai, M.D.</last_name>
      <phone>+8602984775193</phone>
      <email>mingbai1983@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shiren Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>December 31, 2018</last_update_submitted>
  <last_update_submitted_qc>December 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shiren sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CRRT</keyword>
  <keyword>liver failure</keyword>
  <keyword>filter lifespan</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

